aspirin has been researched along with Ventricular Dysfunction, Left in 70 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin." | 9.20 | Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. ( Anker, SD; Buchsbaum, R; Cheng, B; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015) |
| " In the present retrospective analysis of the randomized, double-blind, parallel-group, SMILE-4 study we compared the efficacy of zofenopril 60 mg and acetylsalicylic acid (ASA) 100 mg versus ramipril 10 mg and ASA in patients with AMI complicated by left ventricular dysfunction, classified according to a history of hypertension." | 9.17 | Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. ( Ambrosio, G; Ambrosioni, E; Bacchelli, S; Borghi, C; Cicero, AF; Esposti, DD; Omboni, S; Vinereanu, D; Zava, D, 2013) |
| "This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/day) plus ASA (100 mg/day), in 771 patients with LVD (clinical signs of heart failure or a left ventricular ejection fraction <45%) following acute myocardial infarction (AMI)." | 9.16 | Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European stud ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Vinereanu, D, 2012) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 9.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)." | 8.82 | Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004) |
| "The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid." | 7.85 | Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2017) |
| "In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction." | 7.83 | Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2016) |
| "An adverse interaction between aspirin and angiotensin-converting enzyme (ACE) inhibitors is suspected in patients with heart failure, but the effect of combined therapy with these agents on hospital readmission rates is unknown." | 7.71 | Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure. ( Harjai, KJ; Newman, J; Nunez, E; Turgut, T, 2001) |
| "Pretreatment with aspirin did not change the vasodilator responses in any group." | 6.69 | Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction. ( Adnot, S; Belhassen, L; Benacerraf, S; Carville, C; Dubois-Randé, JL; Montagne, O; Sediame, S, 1999) |
| "Participants in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) trials with HF, but not randomized to oral anticoagulation, were categorized as having preserved versus reduced ejection fraction." | 5.20 | Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. ( Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S, 2015) |
| "We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin." | 5.20 | Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. ( Anker, SD; Buchsbaum, R; Cheng, B; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015) |
| " In the present retrospective analysis of the randomized, double-blind, parallel-group, SMILE-4 study we compared the efficacy of zofenopril 60 mg and acetylsalicylic acid (ASA) 100 mg versus ramipril 10 mg and ASA in patients with AMI complicated by left ventricular dysfunction, classified according to a history of hypertension." | 5.17 | Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. ( Ambrosio, G; Ambrosioni, E; Bacchelli, S; Borghi, C; Cicero, AF; Esposti, DD; Omboni, S; Vinereanu, D; Zava, D, 2013) |
| "This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/day) plus ASA (100 mg/day), in 771 patients with LVD (clinical signs of heart failure or a left ventricular ejection fraction <45%) following acute myocardial infarction (AMI)." | 5.16 | Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European stud ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Vinereanu, D, 2012) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 5.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)." | 4.82 | Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004) |
| "We used the Peto-Yusuf method to undertake a systematic overview of data for 22060 patients from six long-term randomised trials of ACE inhibitors to assess whether aspirin altered the effects of ACE inhibitor therapy on major clinical outcomes (composite of death, myocardial infarction, stroke, hospital admission for congestive heart failure, or revascularisation)." | 4.81 | Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. ( Collins, R; Hall, A; Kober, L; Latini, R; Pfeffer, M; Pogue, J; Teo, KK; Torp-Pedersen, C; Yusuf, S, 2002) |
| " New pharmaceutical compounds such as renin inhibitors, angiotensin II receptor antagonists and aldosterone antagonists are bringing new insights not only into the importance of different components of the renin-angiotensin-aldosterone system in heart failure but also into the mode of action of angiotensin-converting enzyme inhibitors." | 4.79 | Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research. ( Cleland, JG; Morgan, K, 1996) |
| "The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid." | 3.85 | Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2017) |
| "In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction." | 3.83 | Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2016) |
| " Anticoagulants are effective in stroke prevention in atrial fibrillation with aspirin being a less effective alternative." | 3.72 | Left ventricular systolic dysfunction and atrial fibrillation in older people in the community--a need for screening? ( Buchalter, M; Burr, ML; Ho, SF; O'Mahony, MS; Steward, JA, 2004) |
| " These results together with other previously published circumstantial evidence urge for a prospective, controlled and randomised trial specifically designed to evaluate optimal oral anticoagulants and aspirin in patients with congestive heart failure." | 3.71 | Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study). ( Admant, P; Aliot, E; Alla, F; Allam, S; Baille, N; Bellanger, P; Breton, Ch; Briançon, S; D'Hôtel, R; Dambrine, P; Dodet, JF; Ducimetière, P; Echemann, M; Fagnani, F; Graille, M; Guize, L; Juillière, Y; Kessler, M; KhalifE, K; Mertès, PM; Neimann, JL; Rebeix, G; Saulnier, JP; Thisse, JY; Trutt, B; Vidal, P; Villemot, JP; Virion, JM; Vuillemin, MCh; Zannad, F, 2002) |
| "An adverse interaction between aspirin and angiotensin-converting enzyme (ACE) inhibitors is suspected in patients with heart failure, but the effect of combined therapy with these agents on hospital readmission rates is unknown." | 3.71 | Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure. ( Harjai, KJ; Newman, J; Nunez, E; Turgut, T, 2001) |
| "The equivalent of the clinically used low (= antiplatelet)-dose aspirin, inhibited collagen deposition in the non-infarcted myocardium in rats with myocardial infarction." | 3.70 | Low-dose aspirin improves in vivo hemodynamics in conscious, chronically infarcted rats. ( Kalkman, EA; Saxena, PR; Schoemaker, RG, 1998) |
| "Pretreatment with aspirin did not change the vasodilator responses in any group." | 2.69 | Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction. ( Adnot, S; Belhassen, L; Benacerraf, S; Carville, C; Dubois-Randé, JL; Montagne, O; Sediame, S, 1999) |
| " However, we know that ejection fraction and symptom class do not always match and that the regulation of warfarin dosing is more difficult in worsening heart failure." | 2.41 | Anticoagulation and heart failure. ( Graham, SP, 2001) |
| "Intermittent left bundle branch block is a conduction disturbance that has been described to be associated with myocardial bridges and cardiac memory." | 1.51 | Multiple myocardial bridges associated with left-ventricular dysfunction, intermittent left bundle branch block, and cardiac memory: A case report. ( Ibarrola, M, 2019) |
| "Chronic myocardial ischemia was induced using a minimally invasive model in 16 landrace pigs." | 1.37 | Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure. ( Abegunewardene, N; Gori, T; Horstick, G; Kreitner, KF; Lehr, HA; Münzel, T; Schmidt, KH; Schreiber, LM; Vosseler, M, 2011) |
| "None experienced strokes or transient ischemic attacks." | 1.35 | Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device. ( Dia, M; Gallagher, C; Silver, MA; Slaughter, MS; Sobieski, MA, 2008) |
| "Stroke is a devastating complication in patients with prosthetic valves, but characterization of its late occurrence from a large cohort is lacking." | 1.32 | Late incidence and determinants of stroke after aortic and mitral valve replacement. ( Bédard, PJ; Goldstein, WG; Hendry, PJ; Masters, RG; Mesana, TG; Pipe, AL; Rubens, FD; Ruel, M, 2004) |
| "Approximately 50% of patients recovering from acute myocardial infarction have significant left ventricular systolic dysfunction and could benefit considerably from the long-term administration of angiotensin-converting enzyme inhibitors." | 1.30 | ACE inhibitors in acute myocardial infarction. ( McMurray, JJ; Murdoch, DR, 1998) |
| "Left ventricular dysfunction was attributed to idiopathic dilated cardiomyopathy in 18 and coronary artery disease in 19 patients." | 1.30 | Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. ( Atar, D; Gurbel, PA; Lowry, DR; Murugesan, SR; O'Connor, CM; Pothula, A; Serebruany, VL, 1999) |
| "The essential goal of medical treatment following myocardial infarction with left ventricular dysfunction must be the prevention of secondary cardiac failure." | 1.29 | [What is the appropriate treatment for myocardial infarction with left ventricular dysfunction?]. ( Caviezel, B; Cohen-Solal, A; Gourgon, R; Himbert, D; Laperche, T, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (14.29) | 18.2507 |
| 2000's | 30 (42.86) | 29.6817 |
| 2010's | 26 (37.14) | 24.3611 |
| 2020's | 4 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Berg, J | 1 |
| Jablonowski, R | 1 |
| Mohammad, M | 1 |
| Solem, K | 1 |
| Borgquist, R | 1 |
| Ostenfeld, E | 1 |
| Arheden, H | 1 |
| Carlsson, M | 1 |
| Merkler, AE | 1 |
| Pearce, LA | 2 |
| Kasner, SE | 1 |
| Shoamanesh, A | 1 |
| Birnbaum, LA | 1 |
| Kamel, H | 1 |
| Sheth, KN | 1 |
| Sharma, R | 1 |
| Valentini, G | 1 |
| Huscher, D | 1 |
| Riccardi, A | 1 |
| Fasano, S | 1 |
| Irace, R | 1 |
| Messiniti, V | 1 |
| Matucci-Cerinic, M | 1 |
| Guiducci, S | 1 |
| Distler, O | 1 |
| Maurer, B | 1 |
| Avouac, J | 1 |
| Tarner, IH | 1 |
| Frerix, M | 1 |
| Riemekasten, G | 1 |
| Siegert, E | 1 |
| Czirják, L | 1 |
| Lóránd, V | 1 |
| Denton, CP | 1 |
| Nihtyanova, S | 1 |
| Walker, UA | 1 |
| Jaeger, VK | 1 |
| Del Galdo, F | 1 |
| Abignano, G | 1 |
| Ananieva, LP | 1 |
| Gherghe, AM | 1 |
| Mihai, C | 1 |
| Henes, JC | 1 |
| Schmeiser, T | 1 |
| Vacca, A | 1 |
| Moiseev, S | 1 |
| Foeldvari, I | 1 |
| Gabrielli, A | 1 |
| Krummel-Lorenz, B | 1 |
| Rednic, S | 1 |
| Allanore, Y | 1 |
| Müeller-Ladner, U | 1 |
| Cherqaoui, B | 1 |
| Koné-Paut, I | 1 |
| Yager, H | 1 |
| Bourgeois, FL | 1 |
| Piram, M | 1 |
| Kinter, CW | 1 |
| Saxon, GE | 1 |
| Ahmad, M | 2 |
| Berhane, H | 1 |
| Gensler, L | 1 |
| Khosroshahi, A | 1 |
| Hage, A | 1 |
| Jacques, F | 1 |
| Chetaille, P | 1 |
| Bourdages, M | 1 |
| Cloutier, K | 1 |
| Perron, J | 1 |
| Houde, C | 1 |
| Ibarrola, M | 1 |
| Lanzillo, C | 1 |
| Di Roma, M | 1 |
| Sciahbasi, A | 1 |
| Minati, M | 1 |
| Maresca, L | 1 |
| Pendenza, G | 1 |
| Romagnoli, E | 1 |
| Summaria, F | 1 |
| Patrizi, R | 1 |
| Di Luozzo, M | 1 |
| Preziosi, P | 1 |
| Lioy, E | 1 |
| Romeo, F | 1 |
| Chen, K | 1 |
| Williams, S | 1 |
| Chan, AK | 1 |
| Mondal, TK | 1 |
| Borghi, C | 4 |
| Ambrosioni, E | 4 |
| Omboni, S | 3 |
| Cicero, AF | 1 |
| Bacchelli, S | 1 |
| Esposti, DD | 1 |
| Vinereanu, D | 4 |
| Ambrosio, G | 5 |
| Zava, D | 1 |
| Blancas Gómez-Casero, R | 1 |
| Quintana Díaz, M | 1 |
| Chana García, M | 1 |
| Martín Parra, C | 1 |
| López Matamala, B | 1 |
| Estébanez Montiel, B | 1 |
| Ballesteros Ortega, D | 1 |
| Martínez González, O | 1 |
| Vigil Escribano, D | 1 |
| Prieto Valderrey, F | 1 |
| Marina Martínez, L | 1 |
| Castro Gallego, O | 1 |
| Adatya, S | 1 |
| Adataya, S | 1 |
| Masri, C | 1 |
| John, R | 1 |
| Eckman, P | 1 |
| Prom, R | 1 |
| Usedom, JE | 1 |
| Dull, RB | 1 |
| Weisel, RD | 1 |
| Nussmeier, N | 1 |
| Newman, MF | 1 |
| Pearl, RG | 1 |
| Wechsler, AS | 1 |
| Pitt, B | 2 |
| Clare, RM | 1 |
| Pieper, KS | 1 |
| Mongero, L | 1 |
| Reece, TL | 1 |
| Yau, TM | 1 |
| Fremes, S | 1 |
| Menasché, P | 1 |
| Lira, A | 1 |
| Harrington, RA | 1 |
| Ferguson, TB | 1 |
| Sandhu, RK | 1 |
| Hohnloser, SH | 1 |
| Pfeffer, MA | 1 |
| Yuan, F | 1 |
| Hart, RG | 3 |
| Yusuf, S | 2 |
| Connolly, SJ | 1 |
| McAlister, FA | 2 |
| Healey, JS | 1 |
| Ye, S | 1 |
| Cheng, B | 1 |
| Lip, GY | 4 |
| Buchsbaum, R | 1 |
| Sacco, RL | 1 |
| Levin, B | 1 |
| Di Tullio, MR | 1 |
| Qian, M | 1 |
| Mann, DL | 1 |
| Pullicino, PM | 1 |
| Freudenberger, RS | 1 |
| Teerlink, JR | 1 |
| Mohr, JP | 1 |
| Graham, S | 1 |
| Labovitz, AJ | 1 |
| Estol, CJ | 1 |
| Lok, DJ | 1 |
| Ponikowski, P | 1 |
| Anker, SD | 2 |
| Thompson, JL | 1 |
| Homma, S | 2 |
| Shyamali, NL | 1 |
| Ranawaka, H | 1 |
| Novo, S | 3 |
| Slaughter, MS | 1 |
| Sobieski, MA | 1 |
| Gallagher, C | 1 |
| Dia, M | 1 |
| Silver, MA | 1 |
| Nakashima, K | 1 |
| Kirsch, ME | 1 |
| Vermes, E | 1 |
| Rosanval, O | 1 |
| Loisance, D | 1 |
| Schwalm, JD | 1 |
| Salehian, O | 1 |
| Eikelboom, JW | 1 |
| Natarajan, MK | 1 |
| Motwani, M | 1 |
| Arya, S | 1 |
| MacDonald, JE | 1 |
| Gale, CP | 1 |
| Metcalfe, E | 1 |
| West, RM | 1 |
| Das, R | 1 |
| Kilcullen, N | 1 |
| Morrell, C | 1 |
| Crook, R | 1 |
| Batin, PD | 1 |
| Hall, AS | 1 |
| Barth, JH | 1 |
| Lemesle, G | 1 |
| Delhaye, C | 1 |
| Abegunewardene, N | 1 |
| Schmidt, KH | 1 |
| Vosseler, M | 1 |
| Kreitner, KF | 1 |
| Schreiber, LM | 1 |
| Lehr, HA | 1 |
| Gori, T | 1 |
| Münzel, T | 1 |
| Horstick, G | 1 |
| El-Menyar, A | 1 |
| AlHabib, KF | 1 |
| Al-Motarreb, A | 1 |
| Hersi, A | 1 |
| Al Faleh, H | 1 |
| Asaad, N | 1 |
| Al Saif, S | 1 |
| Almahmeed, W | 1 |
| Sulaiman, K | 1 |
| Amin, H | 1 |
| Al-Lawati, J | 1 |
| Alsheikh-Ali, AA | 1 |
| AlQahtani, A | 1 |
| Al-Sagheer, NQ | 1 |
| Singh, R | 1 |
| Al Suwaidi, J | 1 |
| Oliveira, LH | 1 |
| Mallmann, FB | 1 |
| Botelho, FN | 1 |
| Paul, LC | 1 |
| Gianotto, M | 1 |
| Abt, Rde B | 1 |
| Silva, NJ | 1 |
| Luize, CM | 1 |
| Nogueira, FL | 1 |
| Carvalho, RS | 1 |
| Paola, AA | 1 |
| Cirenza, C | 1 |
| Swiatkiewicz, I | 1 |
| Kozinski, M | 1 |
| Magielski, P | 1 |
| Gierach, J | 1 |
| Fabiszak, T | 1 |
| Kubica, A | 1 |
| Sukiennik, A | 1 |
| Navarese, EP | 1 |
| Odrowaz-Sypniewska, G | 1 |
| Kubica, J | 1 |
| Cevik, C | 1 |
| Shah, N | 1 |
| Wilson, JM | 1 |
| Stainback, RF | 1 |
| Piotrponikowski, P | 1 |
| Andreotti, F | 1 |
| Filippatos, G | 1 |
| Morais, J | 1 |
| Pullicino, P | 1 |
| Rasmussen, LH | 1 |
| Marín, F | 1 |
| Lane, DA | 1 |
| Teo, KK | 1 |
| Pfeffer, M | 1 |
| Torp-Pedersen, C | 1 |
| Kober, L | 1 |
| Hall, A | 1 |
| Pogue, J | 1 |
| Latini, R | 2 |
| Collins, R | 1 |
| Echemann, M | 1 |
| Alla, F | 1 |
| Briançon, S | 1 |
| Juillière, Y | 1 |
| Virion, JM | 1 |
| Mertès, PM | 1 |
| Villemot, JP | 1 |
| Zannad, F | 1 |
| Aliot, E | 1 |
| Breton, Ch | 1 |
| KhalifE, K | 1 |
| Neimann, JL | 1 |
| Allam, S | 1 |
| Admant, P | 1 |
| Baille, N | 1 |
| Bellanger, P | 1 |
| D'Hôtel, R | 1 |
| Dambrine, P | 1 |
| Dodet, JF | 1 |
| Graille, M | 1 |
| Kessler, M | 1 |
| Rebeix, G | 1 |
| Saulnier, JP | 1 |
| Thisse, JY | 1 |
| Trutt, B | 1 |
| Vidal, P | 1 |
| Vuillemin, MCh | 1 |
| Ducimetière, P | 1 |
| Fagnani, F | 1 |
| Guize, L | 1 |
| Tereshchenko, SN | 1 |
| Aleksandriia, LG | 1 |
| Moiseev, VS | 1 |
| Stöllberger, C | 1 |
| Chnupa, P | 1 |
| Abzieher, C | 1 |
| Länger, T | 1 |
| Finsterer, J | 1 |
| Klem, I | 1 |
| Hartl, E | 1 |
| Wehinger, C | 1 |
| Schneider, B | 1 |
| Wienbergen, H | 1 |
| Gitt, AK | 1 |
| Schiele, R | 1 |
| Juenger, C | 1 |
| Heer, T | 1 |
| Vogel, C | 1 |
| Gottwik, M | 1 |
| Senges, J | 1 |
| Ruel, M | 1 |
| Masters, RG | 1 |
| Rubens, FD | 1 |
| Bédard, PJ | 1 |
| Pipe, AL | 1 |
| Goldstein, WG | 1 |
| Hendry, PJ | 1 |
| Mesana, TG | 1 |
| Ho, SF | 1 |
| O'Mahony, MS | 1 |
| Steward, JA | 1 |
| Burr, ML | 1 |
| Buchalter, M | 1 |
| Gage, BF | 1 |
| van Walraven, C | 1 |
| Pearce, L | 1 |
| Koudstaal, PJ | 1 |
| Boode, BS | 1 |
| Petersen, P | 1 |
| Ezekowitz, J | 1 |
| Humphries, KH | 1 |
| Norris, CM | 1 |
| Tonelli, M | 1 |
| Ghali, WA | 1 |
| Knudtson, ML | 1 |
| Higashikuni, Y | 1 |
| Sata, M | 1 |
| Nagai, R | 1 |
| Chin, BS | 1 |
| Conway, DS | 1 |
| Graham, JJ | 1 |
| Timmis, A | 1 |
| Cooper, J | 1 |
| Ramdany, S | 1 |
| Deaner, A | 1 |
| Ranjadayalan, K | 1 |
| Knight, C | 1 |
| Granger, CB | 1 |
| Steg, PG | 1 |
| Peterson, E | 1 |
| López-Sendón, J | 1 |
| Van de Werf, F | 1 |
| Kline-Rogers, E | 1 |
| Allegrone, J | 1 |
| Dabbous, OH | 1 |
| Klein, W | 1 |
| Fox, KA | 1 |
| Eagle, KA | 1 |
| Feringa, HH | 1 |
| Bax, JJ | 1 |
| Schouten, O | 1 |
| Poldermans, D | 1 |
| Chih, S | 1 |
| McKeown, B | 1 |
| Ferrier, N | 1 |
| Bitar, G | 1 |
| Marcaggi, X | 1 |
| Amat, G | 1 |
| Fu, Y | 1 |
| Wang, Z | 1 |
| Chen, WL | 1 |
| Moore, PK | 1 |
| Zhu, YZ | 1 |
| Jha, AK | 1 |
| Orav, EJ | 1 |
| Li, Z | 1 |
| Epstein, AM | 1 |
| Cohen-Solal, A | 1 |
| Himbert, D | 1 |
| Caviezel, B | 1 |
| Laperche, T | 1 |
| Gourgon, R | 1 |
| Elikowski, W | 1 |
| Psuja, P | 1 |
| Lewandowski, K | 1 |
| Przybył, M | 1 |
| Wendland, M | 1 |
| Wróblewski, D | 1 |
| Jazienicki, B | 1 |
| Przybył, L | 1 |
| Zawilska, K | 1 |
| Cleland, JG | 1 |
| Morgan, K | 1 |
| Schoemaker, RG | 2 |
| Saxena, PR | 2 |
| Kalkman, EA | 2 |
| Barron, HV | 1 |
| Michaels, AD | 1 |
| Maynard, C | 1 |
| Every, NR | 1 |
| Murdoch, DR | 1 |
| McMurray, JJ | 1 |
| Ghali, JK | 1 |
| Maggioni, AP | 1 |
| Benacerraf, S | 1 |
| Carville, C | 1 |
| Adnot, S | 1 |
| Montagne, O | 1 |
| Sediame, S | 1 |
| Belhassen, L | 1 |
| Dubois-Randé, JL | 1 |
| Krumholz, HM | 1 |
| Baker, DW | 1 |
| Ashton, CM | 1 |
| Dunbar, SB | 1 |
| Friesinger, GC | 1 |
| Havranek, EP | 1 |
| Hlatky, MA | 1 |
| Konstam, M | 1 |
| Ordin, DL | 1 |
| Pina, IL | 1 |
| Spertus, JA | 1 |
| Aronow, WS | 1 |
| Ahn, C | 1 |
| Kronzon, I | 1 |
| Gutstein, H | 1 |
| Van Kerckhoven, R | 1 |
| Lancellotti, P | 1 |
| Piérard, LA | 1 |
| Serebruany, VL | 1 |
| Murugesan, SR | 1 |
| Pothula, A | 1 |
| Atar, D | 1 |
| Lowry, DR | 1 |
| O'Connor, CM | 1 |
| Gurbel, PA | 1 |
| Peterson, JG | 1 |
| Topol, EJ | 1 |
| Sapp, SK | 1 |
| Young, JB | 1 |
| Lincoff, AM | 1 |
| Lauer, MS | 1 |
| Graham, SP | 1 |
| Harjai, KJ | 1 |
| Nunez, E | 1 |
| Turgut, T | 1 |
| Newman, J | 1 |
| Edmunds, E | 1 |
| Beevers, DG | 1 |
| Bratzler, DW | 1 |
| Oehlert, WH | 1 |
| Walkingstick, K | 1 |
| Murray, CK | 1 |
| Shook, C | 1 |
| Maranian, AM | 1 |
| Steinhubl, SR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS),[NCT02313909] | Phase 3 | 7,213 participants (Actual) | Interventional | 2014-12-23 | Terminated (stopped due to Study halted early due to no efficacy improvement over aspirin at an interim analysis and very little chance of showing overall benefit if study were completed) | ||
| The Effect Of Acadesine On Clinically Significant Adverse Cardiovascular and Cerebrovascular Events In High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction [NCT00872001] | Phase 3 | 3,080 participants (Actual) | Interventional | 2009-04-30 | Terminated | ||
| Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study[NCT04684212] | 2,931 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| Variation Between Hospitals in Short-term Mortality After Acute Coronary Syndromes: A CALIBER Study[NCT01111071] | 316,648 participants (Actual) | Observational | 2010-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Major bleeding event (as per ISTH), defined as bleeding event that met at least one of following: fatal bleeding; symptomatic bleeding in a critical area or organ (intraarticular, intramuscular with compartment syndrome, intraocular, intraspinal, pericardial, or retroperitoneal); symptomatic intracranial haemorrhage; clinically overt bleeding associated with a recent decrease in the hemoglobin level of greater than or equal to (>=) 2 grams per decilitre (g/dL) (20 grams per liter [g/L]; 1.24 millimoles per liter [mmol/L]) compared to the most recent hemoglobin value available before the event; clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. The results were based on classification of events that have been positively adjudicated as major bleeding events. Incidence rate estimated as number of subjects with incident events divided by cumulative at-risk time, where subject is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.82 |
| Acetylsalicylic Acid 100 mg OD | 0.67 |
All-cause mortality includes all deaths of participants due to any cause. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.88 |
| Acetylsalicylic Acid 100 mg OD | 1.50 |
Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. Cardiovascular death includes death due to hemorrhage and death with undetermined/unknown cause. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms. The diagnosis of myocardial infarction requires the combination of: 1)evidence of myocardial necrosis (either changes in cardiac biomarkers or post-mortem pathological findings); and 2)supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 6.20 |
| Acetylsalicylic Acid 100 mg OD | 5.85 |
Non-major clinically relevant bleeding was defined as non-major overt bleeding but required medical attention (example: hospitalization, medical treatment for bleeding), and/or was associated with the study drug interruption of more than 14 days. The results were based on the outcome events at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 3.52 |
| Acetylsalicylic Acid 100 mg OD | 2.32 |
Intracranial hemorrhage included all bleeding events that occurred in intracerebral, sub arachnoidal as well as subdural or epidural sites. The below table displays results for all randomized participants and the outcomes at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 0.70 |
| Acetylsalicylic Acid 100 mg OD | 0.35 |
Life-threatening bleeding was defined as a subset of major bleeding that met at least one of the following criteria: 1) fatal bleeding; 2) symptomatic intracranial haemorrhage; 3) reduction in hemoglobin of at least 5 g/dl (50 g/l; 3.10 mmol/L); 4) transfusion of at least 4 units of packed red cells or whole blood; 5) associated with hypotension requiring the use of intravenous inotropic agents; 6) necessitated surgical intervention. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.02 |
| Acetylsalicylic Acid 100 mg OD | 0.43 |
Components of composite efficacy outcome (adjudicated) includes stroke (ischemic, hemorrhagic, and undefined stroke, TIA with positive neuroimaging) and systemic embolism. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 5.14 |
| Acetylsalicylic Acid 100 mg OD | 4.78 |
"Disabling stroke is defined as stroke with modified Rankin score (mRS) greater than or equal to (>=) 4 as assessed by investigator. mRS spans 0-6, running from perfect health to death. A score of 0-3 indicates functional status ranging from no symptoms to moderate disability (defined in the mRS as requiring some help, but able to walk without assistance); mRS 4-6 indicates functional status ranging from moderately severe disability (unable to walk or to attend to own bodily needs without assistance)through to death. CV death includes death due to hemorrhage and death with undetermined/unknown cause. Diagnosis of myocardial infarction requires combination of: 1) evidence of myocardial necrosis either changes in cardiac biomarkers or post-mortem pathological findings); 2) supporting information derived from clinical presentation, electrocardiographic changes, or results of myocardial or coronary artery imaging." (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) | ||||
|---|---|---|---|---|---|
| Stroke | Ischemic stroke | Disabling stroke | CV death(includes death due to hemorrhage) | Myocardial infarction | |
| Acetylsalicylic Acid 100 mg OD | 4.71 | 4.56 | 0.84 | 0.66 | 0.67 |
| Rivaroxaban 15 mg OD | 5.11 | 4.71 | 1.20 | 0.99 | 0.49 |
Incidence of all-cause death, non-fatal stroke, or need for mechanical support for SLVD (any component and composite) through post-operative Day 28 during and following CABG and administration of acadesine or placebo. Components defined as follows: All-cause death: Death from any cause, Non-fatal Stoke: occurrence of a stoke that was confirmed and adjudicated by Clinical Endpoints Committee that did not result in death, and Mechanical Support for SLVD: New use of any mechanical support for ≥1 hour for treatment of low cardiac output. (NCT00872001)
Timeframe: Up to Post-Operative Day 28
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Composite of All Events | All-Cause Death | Non-Fatal Stroke | Need for Mechanical Support for SLVD | |
| Acadesine | 4.9 | 1.9 | 1.7 | 2.2 |
| Placebo | 4.9 | 1.7 | 1.7 | 2.3 |
Incidence of cardiovascular death, non-fatal stroke, and need for mechanical support for SLVD (any component and composite) through post-operative Day 28 during and following CABG and administration of acadesine or placebo. Components defined as follows: Cardiovascular death: Death due to cardiovascular causes, Non-fatal Stroke: occurrence of a stroke that was confirmed and adjudicated by Clinical Endpoints Committee that did not result in death, and Mechanical Support for SLVD: New use of any mechanical support for ≥1 hour for treatment of low cardiac output. (NCT00872001)
Timeframe: Up to Post-Operative Day 28
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Composite of All Events | Cardiovascular Death | Non-Fatal Stroke | Need for Mechanical Support for SLVD | |
| Acadesine | 4.8 | 1.7 | 1.7 | 2.2 |
| Placebo (Normal Saline) | 4.7 | 1.6 | 1.7 | 2.3 |
12 reviews available for aspirin and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review.
Topics: Adolescent; Aspirin; C-Reactive Protein; Case-Control Studies; Child; Child, Preschool; Coronary Dis | 2021 |
Thrombosis and embolism in pediatric cardiomyopathy.
Topics: Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Cardiomyopathy, Restrictive; Child; Disease Manage | 2013 |
Antithrombotics in heart failure with reduced ejection fraction and normal sinus rhythm: an evidence appraisal.
Topics: Anticoagulants; Aspirin; Heart Failure; Humans; Platelet Aggregation Inhibitors; Thromboembolism; Ve | 2014 |
[Decreasing incidence of stent thrombosis].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2011 |
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.
Topics: Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Drug | 2002 |
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cohort Studie | 2004 |
Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; | 1996 |
Contemporary issues in heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Anticoagulants; Aspirin; Communi | 1999 |
How to use ACE-inhibitors, beta-blockers, and newer therapies in AMI.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Follow-Up Studies; H | 1999 |
Anticoagulation and heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Heart Failure; Humans; Platelet A | 2001 |
Should patients with hypertension receive antithrombotic therapy?
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hypertension; Myocardial Infarction; Risk Factors | 2001 |
Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase | 2002 |
12 trials available for aspirin and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Topics: Adult; Aged; Aspirin; Double-Blind Method; Embolic Stroke; Factor Xa Inhibitors; Female; Humans; Mal | 2021 |
Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Captopril; Europe; Female; Humans; Hypertens | 2013 |
Predictors of contemporary coronary artery bypass grafting outcomes.
Topics: Age Factors; Aminoimidazole Carboxamide; Aspirin; Cardiopulmonary Bypass; Cardiovascular Agents; Chi | 2014 |
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopid | 2015 |
Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin.
Topics: Aged; Anticoagulants; Aspirin; Female; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Platele | 2015 |
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies | 2010 |
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European stud
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Chi-Square Distribution; Double- | 2012 |
[Use of trimetazidine in the combined therapy of myocardial infarction with left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Diur | 2002 |
Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Enzyme-Linked Immunosorbent Assay; Female; Heart | 2005 |
Protecting the heart with cardiac medication in patients with left ventricular dysfunction undergoing major noncardiac vascular surgery.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitor | 2006 |
[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
Topics: Adult; Aged; Aspirin; Echocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male | 1996 |
Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction.
Topics: Acetylcholine; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bradykinin; Coronary Angiog | 1999 |
46 other studies available for aspirin and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Ventricular longitudinal shortening is an independent predictor of death in heart failure patients with reduced ejection fraction.
Topics: Aged; Aspirin; Body Mass Index; Cicatrix; Diuretics; Female; Fibrosis; Follow-Up Studies; Heart Fail | 2021 |
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study.
Topics: Adult; Arrhythmias, Cardiac; Aspirin; Cardiomyopathies; Female; Heart Failure; Humans; Incidence; Ma | 2019 |
Multisystem inflammatory syndrome in an adult with involvement of the skin, lymph nodes, muscle, heart, liver and kidneys.
Topics: Acute Kidney Injury; Adult; Anti-Inflammatory Agents; Aspirin; Asymptomatic Infections; Biomarkers; | 2021 |
Thrombolysis of prosthetic mitral valve thrombosis in an infant.
Topics: Aspirin; Coronary Vessels; Female; Fibrinolytic Agents; Heart Septal Defects, Ventricular; Heart Val | 2017 |
Multiple myocardial bridges associated with left-ventricular dysfunction, intermittent left bundle branch block, and cardiac memory: A case report.
Topics: Adrenergic beta-Antagonists; Angina, Stable; Aspirin; Bundle-Branch Block; Cardiotonic Agents; Compu | 2019 |
Cardiac magnetic resonance detection of left ventricular thrombus in acute myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Echocardiogra | 2013 |
[Influence of the combination of antiplatelet agents on the occurrence of early left ventricular insufficiency in patients with acute coronary syndromes without persistent ST-segment elevation].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; F | 2014 |
Loading conditions influence reliability of the echocardiographic ramp test in continuous-flow left ventricular assist devices.
Topics: Aged; Aspirin; Drug Therapy, Combination; Echocardiography; Eptifibatide; Heart-Assist Devices; Hemo | 2013 |
Takotsubo cardiomyopathy after an emotional outburst.
Topics: Antihypertensive Agents; Aspirin; Carbazoles; Carvedilol; Diuretics; Echocardiography; Family Confli | 2015 |
Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Cardiovascular Diseases; Diabeti | 2016 |
Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Chi-Square Distribution; Clinica | 2017 |
Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device.
Topics: Adult; Aged; Aspirin; Brain Diseases, Metabolic; Cardiomyopathy, Dilated; Cause of Death; Cognition | 2008 |
Off-pump replacement of the INCOR implantable axial-flow pump.
Topics: Anticoagulants; Aspirin; Clopidogrel; Equipment Design; Heart-Assist Devices; Humans; Infusion Pumps | 2009 |
Myocardial bridging with a coronary artery aneurysm and left ventricular stunning.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Aneurysm; Exercise Test; Exercise Tolerance; Fibrinol | 2011 |
An assessment of the concentration-related prognostic value of cardiac troponin I following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; A | 2011 |
Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure.
Topics: Animals; Anticoagulants; Aspirin; Clopidogrel; Contrast Media; Coronary Angiography; Coronary Stenos | 2011 |
Prior antiplatelet use and cardiovascular outcomes in patients presenting with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug The | 2012 |
Cross-sectional study of treatment strategies on atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrilla | 2012 |
Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Antihypertensive Agents; Aspirin; Biom | 2012 |
Multiple left ventricular thrombi in a patient with left ventricular noncompaction.
Topics: Anticoagulants; Aspirin; Echocardiography, Doppler, Color; Echocardiography, Transesophageal; Female | 2012 |
Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
Topics: Anticoagulants; Aspirin; Case-Control Studies; Coronary Thrombosis; Europe; Fibrinolytic Agents; Hea | 2012 |
Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Echocardiography; Female; Fibrinoly | 2004 |
Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the Acute Coronary Syndromes [ACOS] Registry).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converti | 2004 |
Late incidence and determinants of stroke after aortic and mitral valve replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aspirin; Atrial Fibrillation; Cerebral | 2004 |
Left ventricular systolic dysfunction and atrial fibrillation in older people in the community--a need for screening?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atrial Fibrill | 2004 |
The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2004 |
Reversible left ventricular hypertrophy after tako-tsubo-like cardiomyopathy.
Topics: Aged; Aspirin; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Chest Pain; Drug Therapy | 2005 |
Impact of the National Service Framework for coronary heart disease on treatment and outcome of patients with acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiac Catheterizat | 2006 |
Medication performance measures and mortality following acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhi | 2005 |
Takotsubo cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathi | 2007 |
[The "tako-tsubo" syndrome: report of two cases].
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cardiomyopathies; Electrocardiography; Female; Humans; H | 2007 |
Cardioprotective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cyclooxygenase 1; Cycloox | 2007 |
Concentration and quality of hospitals that care for elderly black patients.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; | 2007 |
[What is the appropriate treatment for myocardial infarction with left ventricular dysfunction?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Vessels; Hu | 1994 |
Low-dose aspirin improves in vivo hemodynamics in conscious, chronically infarcted rats.
Topics: Adrenergic beta-Agonists; Animals; Aspirin; Drug Administration Schedule; Heart Rate; Hemodynamics; | 1998 |
Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary | 1998 |
ACE inhibitors in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as T | 1998 |
Evaluating quality of care for patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin | 2000 |
Effect of warfarin versus aspirin on the incidence of new thromboembolic stroke in older persons with chronic atrial fibrillation and abnormal and normal left ventricular ejection fraction.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Incidence; Intracranial Embolism | 2000 |
Altered cardiac collagen and associated changes in diastolic function of infarcted rat hearts.
Topics: Adrenergic beta-Agonists; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal | 2000 |
[Acute myocardial infarction: management, prognosis and survival].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non | 2000 |
Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy.
Topics: Aged; Aspirin; Biomarkers; Cardiomyopathy, Dilated; Coronary Disease; Enzyme-Linked Immunosorbent As | 1999 |
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Cyclooxygenase Inhibitors | 2000 |
Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Chi-Square Distribution; Cohort Studies; Cy | 2001 |
Care of acute myocardial infarction in Oklahoma: an update from the Cooperative Cardiovascular Project.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc | 2001 |